IGM is doing so after imvotamab failed to deplete B cell counts — its therapeutic goal — as effectively as the company had hoped in early-stage tests in rheumatoid arthritis and lupus.

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

And IGM, as you mentioned ... which said they were infected -- -- if you now do a -- a rapid antigen or antibody test, and it's negative, then you should do it again. Because if that person ...

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient alternative to blood sampling. However, the complexity of saliva, which ...

The company now lists a lone, Sanofi-partnered IgM antibody asset on its pipeline ... it pivots from an in-house to outsourced analytical testing model. Those moves, coupled with other ...

Obtain a new specimen for IgG and IgM testing. If the new specimen result remains the same, the patient is probably not infected with Toxoplasma gondii. Negative Positive Possible acute infection ...

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...